JP2018511625A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511625A5
JP2018511625A5 JP2017553410A JP2017553410A JP2018511625A5 JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5 JP 2017553410 A JP2017553410 A JP 2017553410A JP 2017553410 A JP2017553410 A JP 2017553410A JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5
Authority
JP
Japan
Prior art keywords
kit
hyperglycemia
chemotherapy
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/028055 external-priority patent/WO2016168802A2/en
Publication of JP2018511625A publication Critical patent/JP2018511625A/ja
Publication of JP2018511625A5 publication Critical patent/JP2018511625A5/ja
Pending legal-status Critical Current

Links

JP2017553410A 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬 Pending JP2018511625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168000A Division JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Publications (2)

Publication Number Publication Date
JP2018511625A JP2018511625A (ja) 2018-04-26
JP2018511625A5 true JP2018511625A5 (cg-RX-API-DMAC10.html) 2019-01-10

Family

ID=57126369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553410A Pending JP2018511625A (ja) 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Country Status (14)

Country Link
US (2) US20160303056A1 (cg-RX-API-DMAC10.html)
EP (2) EP4299061A3 (cg-RX-API-DMAC10.html)
JP (2) JP2018511625A (cg-RX-API-DMAC10.html)
KR (1) KR20180002677A (cg-RX-API-DMAC10.html)
CN (1) CN107613979A (cg-RX-API-DMAC10.html)
AU (1) AU2016248443B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017022244A2 (cg-RX-API-DMAC10.html)
CA (2) CA3108664A1 (cg-RX-API-DMAC10.html)
HK (1) HK1249858A1 (cg-RX-API-DMAC10.html)
IL (1) IL255026A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017013133A (cg-RX-API-DMAC10.html)
RU (1) RU2734774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016168802A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201707710B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291693A4 (en) * 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
KR20180136551A (ko) 2016-05-11 2018-12-24 유니버시티 오브 써던 캘리포니아 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd)
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
EP3963599B1 (en) 2019-04-30 2026-06-03 University of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル-ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー/ドリンク
WO2022008943A1 (ru) * 2020-07-10 2022-01-13 Елена Анатольевна МАРТЫНОВА Способ проведения курса голодания для тяжелобольных пациентов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
CA2900782C (en) * 2013-02-12 2022-09-27 University Of Southern California Methods and diets to protect against chemotoxicity and age related illnesses
RU2727960C2 (ru) * 2013-07-01 2020-07-28 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用

Similar Documents

Publication Publication Date Title
Chi et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer
RU2017136423A (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
Foy et al. Targeting DNA damage in SCLC
Lewis et al. Feeding tube use in patients with head and neck cancer
KR102154458B1 (ko) 공복 조건들 하에서의 타시멜테온의 투여
JP2011144190A (ja) 抗癌剤の効果増強剤
Roy et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
JP2017503846A5 (cg-RX-API-DMAC10.html)
JP2018503644A5 (cg-RX-API-DMAC10.html)
Hershcovici et al. Dexlansoprazole MR–a review
Dubrey et al. Digital clubbing: forms, associations and pathophysiology
Farhat et al. Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient
ES2841981T3 (es) Antihistamínico para su uso en el tratamiento del cáncer de mama
Sugimoto et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)
Hoang et al. Palliative treatment for advanced biliary adenocarcinomas with combination dimethyl sulfoxide–sodium bicarbonate infusion and S-adenosyl-l-methionine
Paz-Ares et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
Chalasani Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations
Chaudhary et al. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer
Kolb et al. Effective use of tocilizumab for the treatment of steroid‐refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin‐6
Tansel et al. New insight into an effective treatment of marginal ulceration after Roux-en-Y gastric bypass
Crumbaker et al. Dose considerations for anti‐cancer drugs in metastatic prostate cancer
Melichar et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial
JP2020512408A5 (cg-RX-API-DMAC10.html)
Sardi et al. Successful treatment with a low-dose cisplatin–etoposide regimen for patients with diencephalic syndrome
JP2025509613A5 (cg-RX-API-DMAC10.html)